Recursion Pharmaceuticals price target raised to $5.50 from $5 at Morgan Stanley
Morgan Stanley raised the firm’s on Recursion Pharmaceuticals () to $5.50 from $5 and keeps an Equal Weight rating on the shares.
🚀🚀🚀
u/Foreign-Industry-841 — 8 days ago